bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
तुलना करने के लिए मीट्रिक्स | BIAF | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधBIAFपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.6x | −3.7x | −0.5x | |
PEG अनुपात | −0.01 | −0.53 | 0.00 | |
क़ीमत/बुक | 1.3x | 7.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 1.5x | 8.2x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 63.9% | 54.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 10.5% | 7.6% | अनलॉक करें |